Skip to main content

Usana Health Sciences Value Stock - Dividend - Research Selection

Usana health sciences

ISIN: US90328M1071 , WKN: 923145

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

General

 

USANA Health Sciences, Inc., a Utah corporation, was founded in 1992 by Myron W. Wentz, Ph.D. We develop and manufacture high-quality, science-based nutritional and personal care products with a primary focus on promoting long-term health and reducing the risk of chronic degenerative disease. In so doing, we are committed to continuous product innovation and sound scientific research. We have operations in 19 markets worldwide, where we distribute and sell our products by way of direct selling. We have chosen this distribution method as we believe it is the most conducive to meeting our vision as a company, which is improving the overall health and nutrition of individuals and families around the world. Our net sales in fiscal year 2014 were $790.5 million, of which 81.8% were in markets outside of the United States. As a U.S.-based multi-national company with an expanding international presence, our operating results are sensitive to currency fluctuations, as well as economic and political conditions in markets throughout the world. Additionally, we are subject to the various laws and regulations in the United States, China, and the other markets in which we operate with respect to the products that we sell and to our method of distribution.

 

Our customer base comprises two types of customers: "Associates" and "Preferred Customers." Associates share in our company vision by acting as independent distributors of our products in addition to purchasing our products for their personal use. Preferred Customers purchase our products strictly for personal use and are not permitted to resell or to distribute the products. As of January 3, 2015, we had 349,000 active Associates and 81,000 active Preferred Customers worldwide.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


USANA Launches Next-Generation Celavive Skincare: Advanced Formulas, Expert Ambassadors, Proven Results

2025-09-11
USANA (NYSE: USNA), a global leader in cellular nutrition, has unveiled the next evolution of its Celavive skincare brand. The launch includes potent new offerings, enhanced formulas, and the recruitment of two globally acclaimed beauty authorities as international spokespeople. This new era of Celavive combines advanced science with real-world expertise to help people everywhere achieve their most youthful, glowing skin. The updated Celavive range merges cutting-edge scientific research with pr

5 Undervalued Stocks That Are Worth Buying in September

2025-09-09
StoneCo, USANA Health Sciences, KT, PagSeguro Digital and Itron stand out as undervalued picks with solid growth prospects this September.

Should Value Investors Buy Grifols (GRFS) Stock?

2025-09-08
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

LifeVantage: Downgrading On Disappointing Results And Outlook - Hold

2025-09-07
Get the latest analysis on LifeVantage's Q4/FY2025 results, MindBody GLP-1 sales, and updated FY2026 guidance.

Kevin Guest Encourages Self-Improvement as Path to Harmony, Fulfillment

2025-09-02
In celebration of September's Self-Improvement Month, Kevin Guest, Executive Chairman of USANA Health Sciences (NYSE: USNA), is inspiring individuals to take meaningful steps toward personal growth and self-betterment. With the U.S. self-improvement industry valued at $12 billion annually, this month is a reminder that the journey to becoming our best selves is both a personal and collective endeavor.

USNA or STVN: Which Is the Better Value Stock Right Now?

2025-08-28
USNA vs. STVN: Which Stock Is the Better Value Option?

3 Cash-Heavy Stocks We Keep Off Our Radar

2025-08-25
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth. Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.

USANA Introduces New and Upgraded Products, Along with Its Health Professional Advisory Council

2025-08-22
USANA, a global leader in cellular nutrition, recently announced innovative new products, significant ingredient reformulations and upgrades, and refreshed packaging. The company also introduced its Health Professional Advisory Council, which will transform the way the company delivers the best health products to millions around the world. All USANA's new and updated products will be available to shop in the coming weeks.

Zacks.com featured highlights StoneCo, CVS Health, Integer and USANA Health Sciences

2025-08-22
StoneCo, CVS Health, Integer and USANA Health Sciences stand out as low P/CF value plays with solid growth forecasts in a volatile market.

4 Value Stocks Every Investor Should Hold in Volatile Times

2025-08-21
StoneCo, CVS, Integer Holdings and USANA emerge as attractive value stocks with low cash-flow ratios and solid growth outlooks.